Embark on a new journey! CMS Pharma achieved a secondary listing on the Singapore Exchange mainboard today.
A Bright New Chapter! CMS Pharma Achieves Dual Listing on Singapore Exchange Mainboard
On the morning of July 15, CMS Pharma Holdings Limited ("CMS Pharma" or "the Group") officially rang the bell for its listing on the Singapore Exchange (Stock Abbreviation: CMS, Stock Code: 8A8).
Nearly a hundred representatives from global professional institutions, shareholders, partners, and employees witnessed this strategic milestone. Following its successful listing on the Hong Kong Stock Exchange Mainboard in September 2010, CMS Pharma has once again made a grand entrance onto the international capital platform, attracting funds focused on Asia-Pacific investments and local Southeast Asian capital to optimize its shareholder structure. This also marks a significant milestone in the Group's deep-rooted expansion into emerging markets and its advancement of the Industrial Internationalization Strategy.
At the listing ceremony, Mr. Lin Gang, Chairman and CEO of CMS Pharma, delivered a speech: "The dual listing in Singapore represents a critical step in CMS Pharma's Asia-Pacific strategy, demonstrating our determination to extend China's market advantages across the entire Asia-Pacific region and deepen our presence in Southeast Asia and the Middle East. This not only supports CMS Pharma's comprehensive and sustainable development in the Asia-Pacific market but also enhances the company's international influence and competitiveness, enabling us to reach a broader patient population with high-quality, affordable medication options."
The New CMS Pharma: A New Rise
Over its 33-year journey, CMS Pharma has undergone three strategic transformations to adapt to external ecosystems: from "China's Largest CSO" (1992-2010), to "Transition from CSO to Pharma" (2010-2018), and since 2018, the establishment of three core strategies—Innovation-Driven, Specialty Breakthroughs, and Industrial Internationalization—propelling the upgrade and iteration of the "New CMS Pharma" with full momentum.
CMS Pharma has established a full life-cycle management system for pharmaceutical products, covering every stage from target identification to clinical development, product registration, and commercialization. The Group focuses on FIC and BIC innovative products, meticulously building a pipeline of approximately 40 differentiated innovative products, five of which have been approved and successfully commercialized in China. With the impact of centralized procurement largely resolved, CMS Pharma has entered a new cycle of high-quality, sustainable development driven by exclusive and innovative drugs.
In specialty areas, the Group concentrates on cardiovascular, digestive, ophthalmology, and dermatology, continuously deepening product layouts and expert networks. Notably, the Group's dermatology business, "Dermagen Pharmaceuticals," has emerged as a leader in its niche and plans to pursue an independent listing on the Hong Kong Stock Exchange Mainboard.
Industrial Internationalization: Synergizing R&D, Production, and Sales Across the Chain
Since 2022, CMS Pharma has launched its "Industrial Internationalization" strategy, leveraging its strengths and resources in the Chinese market to expand into emerging markets. With Singapore as a hub, the Group has established a localized cluster encompassing CMS R&D, PharmaGend, and Rxilient, achieving full-chain synergy in "R&D, production, and sales" to deepen and broaden its market reach across the Asia-Pacific region.
Internationalization of Commercialization System: Rxilient serves as a platform for drug introduction, development, and marketing, operated by a professional and experienced localized team headquartered in Singapore. Its business has expanded to 14 countries and regions, including Malaysia, Thailand, Vietnam, the Philippines, Indonesia, and the Middle East, helping partners from China, the U.S., and Europe bring innovative drugs to emerging markets while introducing more high-quality, affordable treatment options locally. To date, Rxilient has submitted nearly 20 drug and medical device marketing applications in Southeast Asia, the Middle East, and Greater China, covering dermatology, ophthalmology, oncology, autoimmune diseases, and central nervous system disorders.
Internationalization of Production System: PharmaGend, an international CDMO platform based in Singapore, boasts a 30,000-square-meter production facility capable of manufacturing tablets, capsules, and other dosage forms, with plans to expand into injectables, ointments, and nasal sprays. The facility has received international certifications from the FDA and HSA, enabling high-standard drug manufacturing for global markets.
Structural factors such as a large population base, expanding healthcare coverage, and rising chronic disease burdens are driving Southeast Asia and the Middle East to become new growth engines for the global pharmaceutical industry. Leveraging its full-chain ecosystem, CMS Pharma is gradually establishing a new model for Chinese pharmaceutical companies to expand overseas, not only empowering its own product growth in emerging markets but also providing global partners with a reliable one-stop landing mechanism, injecting additional growth momentum into the Group.
Looking ahead, CMS Pharma will continue to advance its three core strategies to build the long-term value system of the "New CMS Pharma," enhancing the accessibility of pharmaceutical innovation, benefiting more patients, achieving sustainable and healthy development, and delivering substantial value returns to investors.
CMS Pharma Disclaimer and Forward-Looking Statements
This news is not intended to promote any product and is not for advertising purposes. This news does not recommend any drugs, medical devices, and/or indications. For specific disease diagnosis and treatment information, please follow the advice or guidance of doctors or other healthcare professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient's specific circumstances and in accordance with the drug instructions.
This news prepared by CMS Pharma does not constitute an offer or invitation to purchase or subscribe for any securities, nor does it form the basis of or reliance for any contract or other binding commitment. This news is compiled by CMS Pharma based on information and data it deems reliable, but CMS Pharma makes no warranties, express or implied, or other representations regarding the truthfulness, accuracy, completeness, fairness, or reasonableness of the content herein, which should not be relied upon. Certain matters discussed in this news may contain statements regarding CMS Pharma's market opportunities and business prospects, collectively or individually referred to as forward-looking statements. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and assumptions. CMS Pharma does not adopt any forward-looking statements or forecasts made by third parties included in this news and assumes no responsibility for such third-party statements or forecasts.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
